Twist Bioscience Q3 revenue $35M (+65% YoY); raises FY2021 guidance

Twist Bioscience Corp

2022-Q3 EPS reported -$2.32 revenue$94,382,000

Revenue $35.0M vs $21.2M YoY; orders $39.1M (+58% YoY).
Net loss $40.0M ($0.82/share) vs $28.2M ($0.67) YoY.
Gross margin 40%; cash $519.4M; raising FY2021 revenue guidance.
Shipped 107,000 genes (vs 83,000 YoY); acquired iGenomX for NGS tools.
Began shipping synthetic SARS-CoV-2 Delta RNA controls; appointed Dr. Melissa Starovasnik to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.